NZ618062A - Hsp90 combination therapy - Google Patents

Hsp90 combination therapy

Info

Publication number
NZ618062A
NZ618062A NZ618062A NZ61806212A NZ618062A NZ 618062 A NZ618062 A NZ 618062A NZ 618062 A NZ618062 A NZ 618062A NZ 61806212 A NZ61806212 A NZ 61806212A NZ 618062 A NZ618062 A NZ 618062A
Authority
NZ
New Zealand
Prior art keywords
hsp90
inhibitor
pathway
complexes
tumour
Prior art date
Application number
NZ618062A
Other languages
English (en)
Inventor
Gabriela Chiosis
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of NZ618062A publication Critical patent/NZ618062A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
NZ618062A 2011-04-28 2012-04-27 Hsp90 combination therapy NZ618062A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
PCT/US2012/035690 WO2012149493A2 (en) 2011-04-28 2012-04-27 Hsp90 combination therapy

Publications (1)

Publication Number Publication Date
NZ618062A true NZ618062A (en) 2016-04-29

Family

ID=47073116

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ618062A NZ618062A (en) 2011-04-28 2012-04-27 Hsp90 combination therapy

Country Status (12)

Country Link
US (2) US20140315929A1 (enExample)
EP (1) EP2701747A4 (enExample)
JP (3) JP6363502B2 (enExample)
KR (2) KR102027448B1 (enExample)
CN (2) CN109498812A (enExample)
AU (3) AU2012249322B2 (enExample)
BR (1) BR112013027448A2 (enExample)
CA (1) CA2833390A1 (enExample)
EA (1) EA201391587A1 (enExample)
MX (1) MX2013012183A (enExample)
NZ (1) NZ618062A (enExample)
WO (1) WO2012149493A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294725A1 (en) 2011-07-08 2014-10-02 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX2016014365A (es) * 2014-05-02 2017-04-27 Wistar Inst Terapias combinadas dirigidas a mitocondrias para la terapia contra cancer.
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN107849616B (zh) * 2015-04-13 2022-03-29 普梭梅根公司 用于功能特征相关的状况的微生物组来源的表征、诊断和治疗的方法及系统
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
JP7187035B2 (ja) * 2016-08-03 2022-12-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ
RU2019127350A (ru) * 2017-02-03 2021-03-03 ЭйАй ТЕРАПЬЮТИКС, ИНК. Способы лечения рака с использованием ингибиторов hsp90
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
IL299893A (en) 2017-06-20 2023-03-01 Madrigal Pharmaceuticals Inc prescribed medications
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
WO2021252490A2 (en) * 2020-06-11 2021-12-16 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
CN116615422A (zh) * 2020-10-14 2023-08-18 珃诺生物医药科技(杭州)有限公司 用于靶向蛋白降解的方法和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
KR20150091434A (ko) * 2007-07-30 2015-08-10 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
WO2010006072A2 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
JP2012510442A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
EP2443123B1 (en) * 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
ES2608670T3 (es) * 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
NZ604040A (en) * 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors

Also Published As

Publication number Publication date
AU2017272303A1 (en) 2018-01-04
JP6363502B2 (ja) 2018-07-25
JP2014523516A (ja) 2014-09-11
CA2833390A1 (en) 2012-11-01
BR112013027448A2 (pt) 2020-09-01
WO2012149493A3 (en) 2014-05-08
MX2013012183A (es) 2014-05-27
JP2017036288A (ja) 2017-02-16
CN109498812A (zh) 2019-03-22
KR20140059757A (ko) 2014-05-16
EA201391587A1 (ru) 2014-08-29
AU2012249322B2 (en) 2018-01-04
KR20190112839A (ko) 2019-10-07
WO2012149493A2 (en) 2012-11-01
JP2018153194A (ja) 2018-10-04
US20220074941A1 (en) 2022-03-10
AU2020200262A1 (en) 2020-02-06
JP6375345B2 (ja) 2018-08-15
US20140315929A1 (en) 2014-10-23
CN103998935B (zh) 2018-10-16
KR102196424B1 (ko) 2020-12-30
CN103998935A (zh) 2014-08-20
AU2012249322A1 (en) 2013-12-12
EP2701747A4 (en) 2015-04-01
KR102027448B1 (ko) 2019-10-01
EP2701747A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
NZ618062A (en) Hsp90 combination therapy
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
MY195289A (en) Anti IL-36R Antibodies
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2011085039A3 (en) Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
CA2839195C (en) Chelated psma inhibitors
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX341734B (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
PH12014502406B1 (en) Anti-il-23p19 antibodies
EP2721033A4 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
EA201790882A1 (ru) Способы и композиции для терапии рака печени
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2011088385A3 (en) Compositions and methods for detecting cancer
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2011101634A3 (en) Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist
BR112014001979A2 (pt) uso do anticorpo i-3859 para a detecção e diagnóstico de câncer
MX340392B (es) Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
WO2015069883A3 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy
WO2013066944A3 (en) Biomarkers for cancer characterization and treatment

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 APR 2019 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20161130

LAPS Patent lapsed